LifeSpan Announces Agreement with Pfizer
Complete the form below to unlock access to ALL audio articles.
LifeSpan BioSciences, Inc. has announced a multi-year agreement with Pfizer Inc. Under the terms of the agreement, Pfizer will gain access to all the features of the DrugTarget Database™, including informatics on 3200 genes, 852 comprehensive immunohistochemistry (IHC) reports with localization information on 400 potential drug targets selected by pharmaceutical company subscribers, and innovative search and sort tools.
In addition, Pfizer will nominate at least 60 new targets to be studied by IHC and published in the consortium database.
LifeSpan will continue to build the database by publishing localization data on an undisclosed number of additional targets each year.
LifeSpan’s vision is to achieve a comprehensive human tissue localization resource for all therapeutically important proteins. With current subscribers, LifeSpan expects to add over 200 targets to the database.
In addition, LifeSpan plans to add new subscribers, substantially increasing this number. The DrugTarget Database™ is designed to enhance the ability of pharmaceutical companies to effectively identify and validate new targets.
The LifeSpan DrugTarget Database™ is LifeSpan’s next generation database following its GPCR and NHR family databases.
In addition to having access to the previously generated data, subscribers to the DrugTarget Database will nominate targets they feel may be of therapeutic relevance, regardless of family.
Significant growth is expected in the ion channel, kinase, phosphatase, protease, phosphodiesterase, and transporter families, as well as many others.
For each protein studied, LifeSpan will provide IHC localization information in 75 human normal and diseased tissues at the cellular level, often using custom generated antibodies.
The DrugTarget Database™ has been further enhanced by the addition of detailed antibody validation reports (IHC results on 20+ normal tissues and target-relevant controls), the use of alternative confirmatory methods (westerns and transfection assays), and an expansion of existing data mining tools.
